Reconstituted HDL: Drug Delivery Platform for Overcoming Biological Barriers to Cancer Therapy

Drug delivery to malignant tumors is limited by several factors, including off-target toxicities and suboptimal benefits to cancer patient. Major research efforts have been directed toward developing novel technologies involving nanoparticles (NPs) to overcome these challenges. Major obstacles, howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Raut, Sangram, Mooberry, Linda, Sabnis, Nirupama, Garud, Ashwini, Dossou, Akpedje Serena, Lacko, Andras
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196266/
https://www.ncbi.nlm.nih.gov/pubmed/30374303
http://dx.doi.org/10.3389/fphar.2018.01154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196266/
https://www.ncbi.nlm.nih.gov/pubmed/30374303
http://dx.doi.org/10.3389/fphar.2018.01154

Ejemplares similares